Latest Echo Therapeutics (ECTE) Headlines
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.
Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors.
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference
PR Newswire - Thu Feb 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Echo's Executive Chairman and Interim CEO, will participate in the Leerink Swann 2014 Global Healthcare Conference in New York, New York.
Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
Natus Medical Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:20PM CST
Natus Medical reported fourth-quarter 2013 adjusted earnings per share (EPS) of 37 cents, surpassing the Zacks Consensus Estimate of 32 cents. It also provided its revenue and EPS outlook for full year 2014.
Varian, Toshiba Sign Supply Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 2:30PM CST
Varian Medical Systems has forged a three-year agreement with Toshiba Medical Systems to supply medical imaging components to the latter.
Intuitive Surgical Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 6:00PM CST
On Jan 24, Zacks Investment Research upgraded Intuitive Surgical, Inc. to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell).
Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fts4bc/corticosteroidres) has announced the addition of the "Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013" report to their offering. 'Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Corticosteroid-Responsive Dermatoses, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corticosteroid-Responsive Dermatoses. Scope - A snapshot of the global therapeutic scenario for Corticosteroid-Responsive Dermatoses. - A review of the Corticosteroid-Responsive Dermatoses products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Corticosteroid-Responsive Dermatoses pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Corticosteroid-Responsive Dermatoses. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Corticosteroid-Responsive Dermatoses pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Echo Therapeutics, Inc. Nuvo Research Inc. Foamix Ltd. For more information visit http://www.researchandmarkets.com/research/ft...steroidres About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Echo Therapeutics Up 7.0%, Shares Break Through Resistance (ECTE)
Comtex SmarTrend(R) - Thu Jan 23, 11:42AM CST
Echo Therapeutics (NASDAQ:ECTE) is one of today's best performing low-priced stocks, up 7.0% to $3.98 on 1.0x average daily volume. Thus far today, Echo Therapeutics has traded 466,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's -1.2%) and outperformed the S&P 500 (7.0% to the S&P's -1.1%) during today's trading.
Echo Therapeutics Applies for CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 6:15PM CST
CE Marking implies a medical device's compliance with European Union legislation and directives with respect to safety, health, environmental and consumer protection
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference
PR Newswire - Wed Jan 15, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference.
Echo Therapeutics Hires Product Development Management Executive
PR Newswire - Tue Jan 14, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Thomas Bishop has joined Echo Therapeutics' management team as Vice President of Product Development. Mr. Bishop, an accomplished product development executive with more than thirty years' experience, joins Echo at a critical stage in the Company's growth. He will lead the execution of Echo's product roadmap strategy and reports directly to Robert F. Doman, Echo's Executive Chairman and Interim CEO.
Echo Therapeutics Submits CE Mark Technical File for its Symphony® CGM System
PR Newswire - Mon Jan 13, 7:54AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has submitted a Conformite Europeenne (CE) Mark Technical File to its European Notified Body to obtain market approval for its Symphony CGM System in the hospital critical care environment. CE Marking indicates a medical device's compliance with European Union (EU) legislation and directives with respect to safety, health, environmental and consumer protection and is necessary for commercialization in countries in the EU. The Company anticipates receiving CE Marking in the 2nd quarter of 2014.
CES 2014: Altair Semiconductor Partners with Ecrio for Commercial VoLTE Solution
PR Newswire - Tue Jan 07, 9:30AM CST
Altair Semiconductor, the world's leading developer of high-performance, single-mode LTE chipsets, and Ecrio, the leading provider of 4G LTE real time communications client software for the mobile industry, today announced a partnership to provide an integrated solution bringing together Altair's LTE chipset and Ecrio's FlexIMS(TM) based Voice over LTE (VoLTE) software. The new product enables high definition voice communications to run over LTE networks in a low power and cost optimized architecture.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.
Echo Therapeutics to Present at the 26th Annual ROTH Capital Conference
PR Newswire - Mon Mar 03, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at the upcoming 26th Annual ROTH Capital Conference.
Echo Therapeutics names Michael M. Goldberg to board
M2 - Mon Mar 03, 6:33AM CST
Us-based medical device company Echo Therapeutics Inc (Nasdaq:ECTE) announced on Friday the appointment of Michael M Goldberg, MD, to the company's board of directors.
Echo Therapeutics elects Dr Michael M. Goldberg to board
M2 - Mon Mar 03, 5:21AM CST
Medical device company Echo Therapeutics (NasdaqCM:ECTE) revealed on Friday that Dr Michael M. Goldberg, MD has been appointed to its board of directors.
Echo Therapeutics Adds New Member to Board of Directors
PR Newswire - Fri Feb 28, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Michael M. Goldberg, M.D., has been appointed to Echo's Board of Directors.
Mycosis Fungoides - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 10, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/x4qbsj/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2013" report to their offering. 'Mycosis Fungoides - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mycosis Fungoides, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycosis Fungoides. Scope - A snapshot of the global therapeutic scenario for Mycosis Fungoides. - A review of the Mycosis Fungoides products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mycosis Fungoides pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mycosis Fungoides Overview Therapeutics Development Pipeline Products for Mycosis Fungoides - Overview Pipeline Products for Mycosis Fungoides - Comparative Analysis Mycosis Fungoides - Therapeutics under Development by Companies Mycosis Fungoides - Therapeutics under Investigation by Universities/Institutes Mycosis Fungoides - Pipeline Products Glance Late Stage Products Clinical Stage Products Mycosis Fungoides - Products under Development by Companies Mycosis Fungoides - Products under Investigation by Universities/Institutes Mycosis Fungoides - Companies Involved in Therapeutics Development Mycosis Fungoides - Therapeutics Assessment Drug Profiles interferon gamma-1a - Drug Profile brentuximab vedotin - Drug Profile brentuximab vedotin - Drug Profile methotrexate-AzoneTS - Drug Profile Genetically Modified T Cells-1138 - Drug Profile CIGB-128 - Drug Profile Mycosis Fungoides - Recent Pipeline Updates Mycosis Fungoides - Product Development Milestones Featured News & Press Releases List of Tables List of Figures Companies Mentioned Shionogi & Co., Ltd. Seattle Genetics, Inc. Echo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/x4..._fungoides About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Approval for DexCom's G4 PLATINUM - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 4:10PM CST
DexCom G4 PLATINUM gets FDA approval for use in children affected with diabetes aged between 2 and 17 years.
Echo Therapeutics to Participate in the Leerink Swann 2014 Global Healthcare Conference
PR Newswire - Thu Feb 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Echo's Executive Chairman and Interim CEO, will participate in the Leerink Swann 2014 Global Healthcare Conference in New York, New York.
Natus Medical Upped to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 04, 2:00PM CST
On Jan 31, Zacks Investment Research upgraded Natus Medical to a Zacks Rank #1 (Strong Buy).
Natus Medical Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 2:20PM CST
Natus Medical reported fourth-quarter 2013 adjusted earnings per share (EPS) of 37 cents, surpassing the Zacks Consensus Estimate of 32 cents. It also provided its revenue and EPS outlook for full year 2014.
Varian, Toshiba Sign Supply Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 2:30PM CST
Varian Medical Systems has forged a three-year agreement with Toshiba Medical Systems to supply medical imaging components to the latter.
Intuitive Surgical Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 6:00PM CST
On Jan 24, Zacks Investment Research upgraded Intuitive Surgical, Inc. to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell).
Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fts4bc/corticosteroidres) has announced the addition of the "Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013" report to their offering. 'Corticosteroid-Responsive Dermatoses - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Corticosteroid-Responsive Dermatoses, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corticosteroid-Responsive Dermatoses. Scope - A snapshot of the global therapeutic scenario for Corticosteroid-Responsive Dermatoses. - A review of the Corticosteroid-Responsive Dermatoses products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Corticosteroid-Responsive Dermatoses pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Corticosteroid-Responsive Dermatoses. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Corticosteroid-Responsive Dermatoses pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Echo Therapeutics, Inc. Nuvo Research Inc. Foamix Ltd. For more information visit http://www.researchandmarkets.com/research/ft...steroidres About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Echo Therapeutics Up 7.0%, Shares Break Through Resistance (ECTE)
Comtex SmarTrend(R) - Thu Jan 23, 11:42AM CST
Echo Therapeutics (NASDAQ:ECTE) is one of today's best performing low-priced stocks, up 7.0% to $3.98 on 1.0x average daily volume. Thus far today, Echo Therapeutics has traded 466,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's -1.2%) and outperformed the S&P 500 (7.0% to the S&P's -1.1%) during today's trading.
Echo Therapeutics Applies for CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 6:15PM CST
CE Marking implies a medical device's compliance with European Union legislation and directives with respect to safety, health, environmental and consumer protection
4 Under-$10 Health Care Stocks Moving Higher
at The Street - Fri Jan 17, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference
PR Newswire - Wed Jan 15, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, will present at "TEN", Noble Financial Capital Markets' Tenth Annual Equity Conference.
Echo Therapeutics Hires Product Development Management Executive
PR Newswire - Tue Jan 14, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Thomas Bishop has joined Echo Therapeutics' management team as Vice President of Product Development. Mr. Bishop, an accomplished product development executive with more than thirty years' experience, joins Echo at a critical stage in the Company's growth. He will lead the execution of Echo's product roadmap strategy and reports directly to Robert F. Doman, Echo's Executive Chairman and Interim CEO.
Echo Therapeutics Submits CE Mark Technical File for its Symphony® CGM System
PR Newswire - Mon Jan 13, 7:54AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has submitted a Conformite Europeenne (CE) Mark Technical File to its European Notified Body to obtain market approval for its Symphony CGM System in the hospital critical care environment. CE Marking indicates a medical device's compliance with European Union (EU) legislation and directives with respect to safety, health, environmental and consumer protection and is necessary for commercialization in countries in the EU. The Company anticipates receiving CE Marking in the 2nd quarter of 2014.
CES 2014: Altair Semiconductor Partners with Ecrio for Commercial VoLTE Solution
PR Newswire - Tue Jan 07, 9:30AM CST
Altair Semiconductor, the world's leading developer of high-performance, single-mode LTE chipsets, and Ecrio, the leading provider of 4G LTE real time communications client software for the mobile industry, today announced a partnership to provide an integrated solution bringing together Altair's LTE chipset and Ecrio's FlexIMS(TM) based Voice over LTE (VoLTE) software. The new product enables high definition voice communications to run over LTE networks in a low power and cost optimized architecture.
